A Multicenter, Randomized, Double-blind, Single-dose Study to Assess the Effect of the QAB149 and NVA237 Combination Versus QAB149 Alone on Inspiratory Capacity in Patients With Moderate or Severe COPD.

Trial Profile

A Multicenter, Randomized, Double-blind, Single-dose Study to Assess the Effect of the QAB149 and NVA237 Combination Versus QAB149 Alone on Inspiratory Capacity in Patients With Moderate or Severe COPD.

Completed
Phase of Trial: Phase III

Latest Information Update: 12 Feb 2016

At a glance

  • Drugs Glycopyrrolate (Primary) ; Indacaterol (Primary)
  • Indications Chronic obstructive pulmonary disease
  • Focus Registrational; Therapeutic Use
  • Acronyms SYNERGY
  • Sponsors Novartis Pharmaceuticals
  • Most Recent Events

    • 04 Mar 2015 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
    • 21 Apr 2014 Planned end date changed from 1 Jan 2014 to 1 Jul 2014 as reported by ClinicalTrials.gov.
    • 09 Oct 2013 Planned End Date changed from 1 Aug 2013 to 1 Jan 2014 as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top